tiprankstipranks
Trending News
More News >
Q32 Bio (QTTB)
NASDAQ:QTTB

Q32 Bio (QTTB) AI Stock Analysis

Compare
826 Followers

Top Page

QT

Q32 Bio

(NASDAQ:QTTB)

41Neutral
Q32 Bio's overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company's current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.
Positive Factors
Clinical Trials
All patients who completed Part A treatment maintained hair after 36 weeks and beyond, with some achieving additional hair growth post-treatment.
Corporate Strategy
The restructuring decision shows confidence in focusing on bempikibart development for alopecia areata patients.
Patient Feedback
Bempi is well tolerated and patients are satisfied with outcomes, indicating potential positive feedback from ongoing studies.
Negative Factors
Financial Performance
QTTB is down -40% YTD as there remains investor cautiousness around bempi's activity in alopecia areata.
Market Comparison
Comparison with Pfizer's JAK inhibitor shows a significantly lower response rate for bempikibart, affecting its valuation.
Stock Valuation
The data is not supportive of bempikibart valuation beyond current assumptions, with a 15% probability of achieving peak sales.

Q32 Bio (QTTB) vs. S&P 500 (SPY)

Q32 Bio Business Overview & Revenue Model

Company DescriptionQ32 Bio (QTTB) is a biotechnology company focused on developing therapies for patients with severe autoimmune and inflammatory diseases. The company operates in the biopharmaceutical sector, leveraging its expertise in immunology to create innovative treatments. Q32 Bio's core products and services involve research and development of monoclonal antibodies and other biologics designed to modulate the immune system and address underlying disease mechanisms.
How the Company Makes MoneyQ32 Bio makes money primarily through the development and commercialization of its therapeutic products. The company's revenue model includes partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone-based payments, and royalties from the sales of developed drugs. Additionally, Q32 Bio may receive funding from grants and research collaborations, which contribute to its operational and developmental expenses. The company's earnings are significantly influenced by the success of its clinical trials and the subsequent approval and commercialization of its therapies.

Q32 Bio Financial Statement Overview

Summary
Q32 Bio is facing significant financial challenges with no recent revenue generation, resulting in negative profit margins and operational inefficiencies. The balance sheet reflects high leverage and negative equity, indicating financial instability. Cash flow issues persist, with negative operating and free cash flows, suggesting the need for strategic restructuring and improved operational efficiency.
Income Statement
35
Negative
Q32 Bio has been experiencing significant challenges in terms of revenue generation, with TTM (Trailing-Twelve-Months) revenue dropping to zero from $1.156 million in 2023. The gross profit margin is negative due to no revenue and persistent losses, indicating operational inefficiencies. Net profit margins have been consistently negative, and the company is struggling with high EBIT and EBITDA losses, reflecting ongoing financial challenges in achieving profitability.
Balance Sheet
40
Negative
The company's balance sheet shows a concerning debt-to-equity ratio due to negative equity, reflecting financial instability. Despite a significant amount of cash and short-term investments, the liabilities are considerably high relative to assets. Equity has been declining, impacting the overall equity ratio negatively. The company needs to address its high leverage and improve equity levels to stabilize its financial foundation.
Cash Flow
45
Neutral
Q32 Bio's cash flow statement reveals negative operating cash flow, indicating cash strain due to unprofitable operations. Although there is a notable increase in financing cash flow, this reliance on external financing might not be sustainable. Free cash flow remains negative, pointing to ongoing challenges in maintaining liquidity and financial flexibility. The free cash flow to net income ratio indicates difficulties in converting income into cash.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
1.16M6.65M33.97M2.70M1.67M
Gross Profit
578.00K4.05M24.43M2.70M1.67M
EBIT
-92.10M-39.23M-36.69M-130.26M-109.94M
EBITDA
-86.50M-38.85M-86.22M-121.36M-103.63M
Net Income Common Stockholders
-112.96M-42.81M-37.56M-128.69M-103.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
82.65M43.89M32.25M217.43M262.39M
Total Assets
306.12M61.77M35.15M263.74M310.57M
Total Debt
50.84M44.73M4.97M15.44M0.00
Net Debt
-37.95M838.00K-27.27M-201.99M-53.77M
Total Liabilities
233.13M192.49M124.36M67.74M52.06M
Stockholders Equity
72.99M-130.71M-89.21M196.00M258.51M
Cash FlowFree Cash Flow
-96.46M-13.44M-33.14M-98.06M-113.19M
Operating Cash Flow
-96.23M-10.96M-32.98M-94.33M-91.36M
Investing Cash Flow
101.33M-2.47M-157.00K204.90M-51.80M
Financing Cash Flow
184.00K30.07M20.11M53.09M158.21M

Q32 Bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.87
Price Trends
50DMA
2.05
Negative
100DMA
4.44
Negative
200DMA
22.27
Negative
Market Momentum
MACD
-0.06
Negative
RSI
47.09
Neutral
STOCH
38.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Negative. The current price of 1.87 is above the 20-day moving average (MA) of 1.77, below the 50-day MA of 2.05, and below the 200-day MA of 22.27, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.09 is Neutral, neither overbought nor oversold. The STOCH value of 38.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QTTB.

Q32 Bio Risk Analysis

Q32 Bio disclosed 86 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Q32 Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.31B3.39-40.42%2.90%18.11%2.25%
42
Neutral
$20.01M-75.07%42.39%
41
Neutral
$22.81M-121.36%-100.00%91.45%
39
Underperform
$27.32M-182.35%-220.54%
33
Underperform
$24.70M-91.76%57.93%
33
Underperform
$30.59M-3159.09%68.75%
32
Underperform
$27.13M-157.19%-0.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
QTTB
Q32 Bio
1.87
-27.17
-93.56%
TPST
Tempest Therapeutics
7.76
-36.96
-82.65%
CMMB
Chemomab Therapeutics
1.31
0.63
92.65%
ANVS
Annovis Bio
1.57
-5.71
-78.43%
PASG
Passage Bio
0.32
-0.98
-75.38%
CGTX
Cognition Therapeutics
0.44
-1.49
-77.20%

Q32 Bio Corporate Events

Executive/Board Changes
Q32 Bio Board Member Mark Iwicki Resigns
Neutral
Apr 25, 2025

On April 25, 2025, Mark Iwicki announced his resignation from the board of directors of Q32 Bio Inc., effective December 31, 2025. He will maintain his roles as Chair of the Board and the Compensation Committee, and as a member of the Audit Committee until then. His resignation is to focus on his CEO role at Inhibikase Therapeutics, Inc., and is not due to any disagreements with Q32 Bio.

Spark’s Take on QTTB Stock

According to Spark, TipRanks’ AI Analyst, QTTB is a Neutral.

Q32 Bio’s overall stock score is low due to significant financial instability, negative revenue, and ongoing losses. The technical analysis shows mixed signals, while the valuation is unattractive with a negative P/E ratio and no dividends. These factors highlight the company’s current financial and operational challenges, suggesting a need for strategic changes to improve its financial health.

To see Spark’s full report on QTTB stock, click here.

Product-Related AnnouncementsBusiness Operations and Strategy
Q32 Bio Restructures to Focus on Bempikibart Development
Neutral
Feb 10, 2025

On February 10, 2025, Q32 Bio announced a strategic restructuring plan to focus on advancing its bempikibart clinical development program for alopecia areata. This involves discontinuing the Phase 2 renal basket trial of ADX-097 and evaluating strategic options for its tissue-targeted complement inhibitor platform. The restructuring includes a reduction in workforce and is expected to extend cash runway to the second half of 2026, while incurring approximately $1.1 million in severance charges. The company plans to initiate an open-label extension and SIGNAL-AA Part B dosing in 2025, with topline data expected in the first half of 2026. These changes aim to maximize the potential of bempikibart in transforming treatment for alopecia areata and potentially other autoimmune conditions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.